Epidermal growth factor in the treatment of diabetic foot ulcers: An update

Perspectives in Vascular Surgery and Endovascular Therapy

Volumn 24, Issue 1, 2012, Pages 37-44

  Tiaka, Elisavet K ^a   Papanas, Nikolaos ^a   Manolakis, Anastassios C ^b   Georgiadis, George S ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

diabetic foot; epidermal growth factor (EGF); growth factors; wound healing

Indexed keywords

ACTOVEGIN; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ANEMIA; ARTICLE; CHILL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC FOOT; DRUG BIOAVAILABILITY; DRUG EFFICACY; EPITHELIUM CELL; EVIDENCE BASED PRACTICE; FEVER; FIBROBLAST; HUMAN; INJECTION SITE PAIN; NAUSEA; PRIORITY JOURNAL; RASH; SEPSIS; SKIN BURNING SENSATION; SKIN IRRITATION; TREMOR; VOMITING; WOUND HEALING;

ADULT; AGED; DIABETIC FOOT; DRUG ADMINISTRATION ROUTES; EPIDERMAL GROWTH FACTOR; EVIDENCE-BASED MEDICINE; HUMANS; MIDDLE AGED; RECOMBINANT PROTEINS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 84861708902     PISSN: 15310035     EISSN: 15310027     Source Type: Journal    
DOI: 10.1177/1531003512442093     Document Type: Article

References (41)

1. Hunt D. Diabetes: foot ulcers and amputations. Clin Evid. 2009 ; 1: 602
2. Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. Acta Clin Belg. 2007 ; 62: 230-238 (Pubitemid 47234752)
3. Papanas N, Maltezos E. Advances in treating the ischaemic diabetic foot. Curr Vasc Pharmacol. 2008 ; 6: 23-28
4. Boulton AJ. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev. 2008 ; 24: S3 - S6
5. Papanas N, Maltezos E. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?. Int J Low Extrem Wounds. 2007 ; 6: 37-53
6. Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002 ; 66: 1655-1662 (Pubitemid 36068123)
7. Gul A, Basit A, Ali SM, et al. Role of wound classification in predicting the outcome of diabetic foot ulcer. J Pak Med Assoc. 2006 ; 56: 444-447 (Pubitemid 44904901)
8. Parisi MC, Zantut-Wittmann DE, Pavin EJ, et al. Comparison of three systems of classification in predicting the outcome of diabetic foot ulcers in a Brazilian population. Eur J Endocrinol. 2008 ; 159: 417-422
9. Tiaka EK, Papanas N, Manolakis AC, Maltezos E. The role of hyperbaric oxygen in the treatment of diabetic foot ulcers [published online ahead of print August 25, 2011]. Angiology. :
10. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006 ; 295: 547-553 (Pubitemid 43200349)
11. Daskalopoulou SS, Athyros VG, Hamilton G, et al. Lipid-lowering therapy in patients with peripheral arterial disease. J Cardiovasc Pharmacol Ther. 2005 ; 10: 145-147 (Pubitemid 40847877)
12. Alnaeb ME, Alobaid N, Seifalian AM, et al. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg. 2006 ; 20: 696-705 (Pubitemid 44953092)
13. Paraskevas KI, Athyros VG, Briana DD, et al. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets. 2007 ; 8: 942-951
14. Gulcan E, Gulcan A, Erbilen E, et al. Statins may be useful in diabetic foot ulceration treatment and prevention. Med Hypotheses. 2007 ; 69: 1313-1315 (Pubitemid 47633051)
15. Cohen S. Isolation of mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new born animal. J Biol Chem. 1962 ; 237: 1555-1562
16. Krishnan K, Arnone B, Buchman A. Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm Bowel Dis. 2011 ; 17: 410-422
17. Yu F-SX, Yin J, Xu K, et al. Growth factors and corneal epithelial wound healing. Brain Res Bull. 2010 ; 81: 229-235
18. Nanney LB. Epidermal and dermal effect of epidermal growth factor during wound repair. J Invest Dermatol. 1990 ; 94: 624-629 (Pubitemid 20141280)
19. Liebmann C. EGF receptor activation by GPCRs: a universal pathway reveals different versions. Mol Cell Endocrinol. 2011 ; 331: 222-231
20. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008 ; 16: 585-601
21. Steed DL Modulating Wound Healing in Diabetes: The Diabetic Foot. 6 th ed.St Louis, MO: Mosby; 2001. St Louis, MO: Mosby ; 2001 :
22. Acosta JB, Savigne W, Valdez C, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J. 2006 ; 3: 232-239
23. Tuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. Int Wound J. 2009 ; 6: 159-166
24. Wong WKR, Lam E, Huang RC, et al. Applications and efficient large-scale production of recombinant human epidermal growth factor. Biotechnol Genet Eng Rev. 2001 ; 13: 51-68
25. Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003 ; 26: 1856-1861 (Pubitemid 36929133)
26. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg. 2006 ; 56: 394-398
27. Viswanathan V, Pendsey S. A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D™ 150) in healing diabetic foot ulcers. Wounds. 2006 ; 18: 186-196 (Pubitemid 44338024)
28. Fernández-Montequín JI, Infante-Cristia E, Valenzuela-Silva C, et al. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007 ; 4: 333-343 (Pubitemid 350264799)
29. Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009 ; 6: 432-443
30. Loot MA, Kenter SB, Au FL, et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol. 2002 ; 81: 153-160 (Pubitemid 34308679)
31. Hehenberger K, Hansson A. High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors. Cell Biochem Funct. 1997 ; 15: 197-201 (Pubitemid 27395286)
32. Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen. 2006 ; 14: 558-565 (Pubitemid 44470072)
33. Zhou LS, Liao ZJ, Zhang Q, et al. Bio-inductive effects of inorganic elements on skin wound healing. Zhonghua Shao Shang Za Zhi. 2005 ; 21: 363-366
34. Steed DL, Goslen JB, Holloway GA, et al. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care. 1992 ; 15: 1598-1604
35. Yuan NB, Long Y, Zhang XX, et al. Study on the mechanism of autologous platelet-rich gel to treat the refractory diabetic dermal ulcers. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 ; 40: 292-294
36. Wang CJ, Ko JY, Kuo YR, et al. Molecular changes in diabetic foot ulcers. Diabetes Res Clin Pract. 2011 ; 94: 105-110
37. Jennings JA, Crews RM, Robinson J, et al. Effect of growth factors in combination with injectable silicone resin particles on the biological activity of dermal fibroblasts: a preliminary in vitro study. J Biomed Mater Res B Appl Biomater. 2010 ; 92: 255-260
38. Amin AH, Abd Elmageed ZY, Nair D, et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest. 2010 ; 90: 985-996
39. Miettinen P, Ormio P, Hakonen E, et al. EGF receptor in pancreatic beta-cell mass regulation. Biochem Soc Trans. 2008 ; 36 (pt 3). 280-285 (Pubitemid 351839316)
40. Brand SJ, Tagerud S, Lambert P, et al. Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin. Pharmacol Toxicol. 2002 ; 91: 414-420 (Pubitemid 36132447)
41. Jun HS. In vivo regeneration of insulin-producing beta-cells. Adv Exp Med Biol. 2010 ; 654: 627-640